DCOY — Decoy Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1615219 ·
Last close
$4.11
Market Cap
$2.19M
52W High
$13.51
52W Low
$3.51
ADV30
499,057
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,283,739 | -2,224,628 | 8,423,275 | 7,820,608 | 4,545,890 |
| Dec 2025 | 0 | — | -9,034,562 | -8,977,655 | 11,056,707 | 10,709,937 | 5,167,738 |
| Sep 2025 | 0 | — | -895,130 | -873,467 | 6,097,032 | 4,809,680 | 1,848,967 |
| Jun 2025 | 0 | — | -965,565 | -957,825 | 1,392,778 | 794,886 | 2,222,502 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,827,188
Investing CF
$964,735
Financing CF
$12,337,862
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-424.68
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-94,442,098
Inventory
—
Receivables
$200,000
ST Investments
—
EBIT TTM
$-12,613,952
Pretax Income TTM
$-12,518,480
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -12,613,952 | -12,518,480 | 11,056,707 | 5,167,738 | — | -4,827,188 |
| Dec 2024 | 0 | -5,734,316 | -5,575,777 | 3,022,974 | 1,511,279 | — | -4,525,337 |
| Dec 2023 | 0 | -12,894,944 | -12,542,693 | 6,586,523 | 1,299,241 | — | -12,846,137 |
| Dec 2022 | 0 | -22,975,231 | -31,607,956 | 14,650,799 | 4,266,191 | — | -17,595,321 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-21,561,494
OpCashFlow TTM
$0
Assets (Latest)
$3,022,974
Forward EPS
$-19.32
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ISCO | International Stem Cell CORP | $2.16M | $0.27 | — |
| AZTR | Azitra, Inc. | $2.15M | $0.13 | — |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $2.22M | $3.80 | — |
| OGEN | ORAGENICS INC | $2.26M | $0.50 | — |
| VCNX | VACCINEX, INC. | $2.28M | $0.85 | — |
News headlines (Yahoo Finance, 1h cache)
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
2026-07-27 13:00 · Yahoo
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
2026-07-15 13:24 · Yahoo
DCOY Stock Nearly Doubled In Value Today – What’s Driving This Mega Rally?
2026-06-29 15:41 · Yahoo
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
2026-06-27 00:11 · Yahoo
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
2026-06-08 12:00 · Yahoo
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
2026-06-03 12:00 · Yahoo
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
2026-06-01 11:00 · Yahoo
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
2026-05-26 12:15 · Yahoo
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
2026-04-27 12:45 · Yahoo
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
2026-04-09 12:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.